Shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) have earned a consensus rating of “Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $10.00.
A number of equities analysts have weighed in on the company. Zacks Investment Research downgraded Vistagen Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 7th. Maxim Group set a $6.00 price target on Vistagen Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 30th. Oppenheimer set a $6.00 price target on Vistagen Therapeutics and gave the stock a “buy” rating in a research report on Sunday, November 4th. Finally, ValuEngine raised Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
NASDAQ:VTGN traded down $0.10 during trading hours on Monday, reaching $1.73. 85,000 shares of the stock were exchanged, compared to its average volume of 670,503. Vistagen Therapeutics has a twelve month low of $0.69 and a twelve month high of $2.65. The company has a market cap of $56.83 million, a P/E ratio of -1.56 and a beta of -1.53.
An institutional investor recently raised its position in Vistagen Therapeutics stock. Vanguard Group Inc. increased its stake in Vistagen Therapeutics Inc (NASDAQ:VTGN) by 42.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 257,465 shares of the company’s stock after buying an additional 77,090 shares during the quarter. Vanguard Group Inc. owned approximately 0.83% of Vistagen Therapeutics worth $373,000 as of its most recent SEC filing. Institutional investors and hedge funds own 7.44% of the company’s stock.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Featured Article: What are defining characteristics of a correction?
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.